INVO Bioscience, Inc. (INVO)
NASDAQ: INVO · IEX Real-Time Price · USD
1.160
+0.060 (5.45%)
At close: Mar 28, 2024, 9:33 AM
1.080
-0.080 (-6.90%)
After-hours: Mar 28, 2024, 4:00 PM EDT
Company Description
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide.
Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body.
INVO Bioscience, Inc. was founded in 2007 and is based in Sarasota, Florida.
INVO Bioscience, Inc.
Country | United States |
Founded | 2007 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 15 |
CEO | Steven M. Shum |
Contact Details
Address: 5582 Broadcast Court Sarasota, Florida 34240 United States | |
Phone | (978) 878-9505 |
Website | invobio.com |
Stock Details
Ticker Symbol | INVO |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001417926 |
CUSIP Number | 44984F302 |
ISIN Number | US44984F4019 |
Employer ID | 20-4036208 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Steven M. Shum | Chief Executive Officer and Director |
Andrea Goren | Chief Financial Officer |
Michael Jos. Campbell | Chief Operating Officer and Vice President of Business Development |
Bojan Mitrovic Ph.D. | Director of Sales US |
Robert Joseph Bowdring Jr. | Treasurer and Secretary |
Terah Krigsvold | Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 27, 2024 | 10-K/A | [Amend] Annual report |
Mar 1, 2024 | 8-K | Current Report |
Feb 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 1, 2024 | 8-K | Current Report |
Jan 16, 2024 | S-4 | Filing |
Jan 10, 2024 | 8-K/A | [Amend] Current report |
Jan 10, 2024 | 8-K | Current Report |
Jan 3, 2024 | 8-K | Current Report |
Dec 28, 2023 | 424B7 | Filing |
Dec 28, 2023 | 8-K | Current Report |